YOLFTbeta
Shuttle Pharmaceuticals Inc

Shuttle Pharmaceuticals Inc

SHPH · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

4.53USD-0.23 (-4.83%)

Price History

Full chart

Market Stats

Previous Close4.76
Open4.64
Day Range4.53 – 4.65
52-Week Range2.58 – 55.90
Volume10.28K
Market Cap2.40M
P/E (TTM)41.10
Forward P/E0.00
EPS0.10
Dividend Yield0.00%
Beta1.22
50-Day Avg3.60
200-Day Avg8.65

About

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Christopher Robert Cooper BBA, M.B.A.
  • Employees2
  • Headquarters401 Professional Drive, Gaithersburg, MD, United States, 20879, USA
  • Websitehttps://www.shuttlepharma.com

Leadership

  • Mr. Christopher Robert Cooper BBA, M.B.A.Interim Co-CEO & Director · b. 1970
  • Dr. Milton Brown CSC, M.D., Ph.D.Co-Founder · b. 1965
  • Mr. Ryan TrasoliniCo-Chief Executive Officer
  • Dr. Mira Jung Ph.D.Co-Founder & Chief Scientific Officer for Biology · b. 1949
  • Ms. Yuying Liang B.A., CPAChief Financial Officer · b. 1991
  • Dr. Tyvin A. Rich M.D.Chief Clinical Officer & Chief Medical Officer · b. 1948
  • Mr. Michael P. Vander HoekVice President for Operations and Regulatory · b. 1960

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue----000000
Cost of Revenue--18.74K18.00K54.95K60.83K5.97K6.81K5.46K290.11K
Gross Profit---18.74K-18.00K-54.95K-60.83K-5.97K-6.81K-5.46K-290.11K
Operating Expense--185.15K568.63K454.57K1.68M2.34M5.89M7.69M11.63M
Operating Income---203.89K-586.63K-509.52K-1.74M-2.34M-5.89M-7.70M-11.92M
EBITDA---183.97K-577.22K-711.15K-1.04M-4.32M-3.99M-7.78M-11.36M
Net Income---213.59K-626.14K-805.73K-1.15M-5.00M-6.59M-9.14M-11.72M
R&D--83655.57K161.77K1.02M1.05M3.52M3.62M4.05M
Interest Expense0010.88K30.92K39.63K50.79K670.61K2.60M1.36M70.83K

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets--121.30K621.27K544.05K651.64K8.65M5.95M2.51M10.48M
Total Liabilities--405.65K593.82K2.23M2.28M975.68K1.90M1.80M8.22M
Total Equity---284.35K27.46K-1.69M-1.63M7.68M4.06M709.15K2.25M
Cash--50.71K352.39K117.15K504.75K8.42M2.58M1.92M334.00K
Total Debt--314.38K400.00K874.28K978.88K748.30K1.09M1.17M232.15K
Net Debt--263.67K47.61K757.13K474.13K-7.67M-1.49M-746.67K-101.86K

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-303.55K-230.07K-202.71K-566.69K-26.83K-300.34K-2.71M-5.58M-7.33M-9.48M
Investing Cash Flow25.43K20.17K--10.82K-10.82K---2.83M2.92M-3.06M
Financing Cash Flow300.00K173.86K160.62K868.37K70.07K687.93K10.62M2.57M3.76M10.95M
Capital Expenditure4.55K4.55K010.82K10.82K4019.05K19.05K5
Free Cash Flow---202.71K-566.69K-37.65K-300.34K-2.71M-5.60M-7.33M-9.48M
Dividends Paid------402.07K-00
FCF to OCF--100.00%100.00%140.32%100.00%100.00%100.34%100.00%100.00%
Dividend Paid to FCF-------14.83%-0.00%0.00%

Earnings

Report DateDec 9, 2016Jun 26, 2017Aug 14, 2017Nov 20, 2017Jul 13, 2022Nov 14, 2022Mar 15, 2023Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Feb 26, 2025May 8, 2025Aug 13, 2025Nov 13, 2025Dec 31, 2025Mar 31, 2026Sep 24, 2026Nov 12, 2026
EPS Estimate0.000.000.000.000.00-----------------
EPS Actual-0.010.000.000.00-0.05-0.02-0.06-143.02-306.34-227.74-204.18-208.48-241.24-396.79-0.40-7.60-3.29-1.05-12.92-4.28-3.84-
Surprise----------------------
Timing----------------------

Key Statistics & Ratios

Market Cap2.40M
Enterprise Value1.22M
Trailing P/E41.10
Forward P/E0.00
Price / Sales0.00
Price / Book0.63
EPS0.10
Book Value6.03
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-9.66M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-90.05%
Return on Assets-49.54%
Shares Outstanding585.13K
Shares Float4.76M
Beta1.22
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
1.93%
Insiders
0.84%
Retail / Other
97.23%

Top Institutional Holders

  • Citadel Advisors Llc
    24.35K2.37%
  • Ikarian Capital, LLC
    68.99K0.67%
  • Geode Capital Management, LLC
    46.22K0.45%
  • BOOTHBAY FUND MANAGEMENT, LLC
    20.36K0.20%
  • Virtu Financial LLC
    12.38K0.12%
  • UBS Group AG
    5.67K0.06%
  • Tower Research Capital LLC
    4.64K0.05%
  • Wall Street Access Asset Management, LLC
    1200.01%
  • Morgan Stanley - Brokerage Accounts
    270.00%
  • Federation des caisses Desjardins du Quebec
    00.00%
  • Citigroup Inc
    00.00%
  • Bank of America Corp
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    3.79K0.38%

Stock Splits

  • Jun 11, 20261:10
  • Jun 16, 20251:25
  • Aug 13, 20241:8